Roughly a year and a half since its last raise, Icosavax scored a fresh goal Wednesday morning in nabbing new funds for its soccer ball-like VLP vaccine tech. And the Seattle-based company is bringing in a high-profile set of new investors.
Icosavax unveiled a $100 million Series B, backed by…
